[Promotion and implementation of respiratory syncytial virus monoclonal antibody in vaccination clinics in Tianjin City]

Zhonghua Yu Fang Yi Xue Za Zhi. 2024 Nov 25:58:1-4. doi: 10.3760/cma.j.cn112150-20240902-00697. Online ahead of print.
[Article in Chinese]

Abstract

Acute lower respiratory infections in infants and young children, caused by respiratory syncytial virus (RSV), represent a significant global public health challenge, characterized by a substantial disease burden. During the winter and spring seasons, various respiratory viruses tend to co-circulate, leading to increased pressure on pediatric healthcare services due to heightened rates of visits and hospitalizations. Currently, there is no approved RSV vaccine available for children worldwide; however, the development and application of long-acting monoclonal antibodies present a promising avenue for the prevention of RSV in this vulnerable population. In June 2024, Tianjin released"Guidelines for the monoclonal antibody of respiratory syncytial virus in Tianjin (2024 version)", which outlines the promotion of monoclonal antibody administration in vaccination clinics throughout the region. The objective of this paper is to provide reference information that may assist in the formulation and implementation of a national RSV immunization strategy.

呼吸道合胞病毒(RSV)引发的婴幼儿急性下呼吸道感染是一个重要的全球公共卫生问题,疾病负担严重。在我国冬春季易并发多种呼吸道病毒叠加流行现象,从而引发儿科的就诊和住院压力。目前全球尚无获批用于儿童的RSV疫苗,而长效单克隆抗体的研发和应用给婴幼儿人群的RSV预防提供了一种新的可能性。2024年6月天津市发布《天津市呼吸道合胞病毒(RSV)单克隆抗体接种指导意见(2024年版)》,现将天津市推动RSV单克隆抗体在预防接种门诊的使用进行梳理介绍,以期为全国性RSV免疫预防策略的制定与实施提供参考信息。.

Publication types

  • English Abstract